AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03997422 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vertical Sleeve Gastrectomy (VSG)
Description: Vertical Sleeve gastrectomy will be performed using five laparoscopic ports using a 40 French Bougie as a template. If a hiatal hernia is identified it will be repaired. This practice has greatly reduced postoperative reflux disease (see human subjects protection). As VSG for patients with a BMI 30.0-34.9 kg/m2 is not covered by insurance the University hospital will cover costs for up to 24 patients.
Study NCT00118170 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib tosylate
Description: Given orally
Study NCT00118170 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT02787512 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Stent
Description: Endoscopic biliary stent insertion
Study NCT02787512 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stent
Description: Endoscopic biliary stent insertion
Study NCT03058458 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PIN201104
Description: IV or SC administration
Study NCT03058458 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: IV or SC administration
Study NCT04347811 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Death Cafe
Description: Death Cafés are a specific form of debriefing that focuses on discussing death, dying, loss, and illness. Nourishment in the form of cake is provided. These sessions may allow for reflection on distressing patient events while developing a sense of community and collaboration among hospital employees.
Study NCT03799315 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Replacement Therapy
Description: All participants randomized to the JUST group will receive training on proper use of nicotine lozenges to aid in smoking cessation. Upon release from jail, participants will receive 2mg nicotine lozenges.
Study NCT03799315 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Counseling
Description: All participants randomized to the JUST group will receive one hour of in-person, individual, guideline-based smoking cessation counseling during their jail stay. Upon release from jail, they will receive four 30-minute counseling phone calls over 3 weeks. These phone calls will take place at 24 hours, day 7, day 14, and day 20.
Study NCT03070730 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Droxidopa
Description: Droxidopa: 100 mg or 300 mg t.i.d
Study NCT01316692 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker identification and analysis
Description: Correlative studies
Study NCT03070730 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Atenolol
Description: Atenolol: 50 mg Q.D.
Study NCT03070730 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Placebos
Description: Placebo: t.i.d
Study NCT03628469 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Proactive Health Support
Description: Active listening, coaching and counselling
Study NCT02471131 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: WATCHMAN Device implantation
Description: The implantation of the device will be done into the left atrial appendage according to the guidelines.
Study NCT01652378 — intervention group
Intervention type: DRUG
Intervention: ondansetron, lidocaine
Description: Ondansetron: Ondansetron (0.15 mg/kg) will be administered through the IV line over 15 min at a constant rate of infusion.~Lidocaine: Lidocaine will be administered as a 2mg/kg initial bolus over 5 minutes followed by a continuous intravenous infusion of lidocaine at a rate of 2mg/kg/hour for 55 min (60 min total infusion).
Study NCT02778776 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metfomin in tablet presentation of 500 mg
Study NCT02778776 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Metfomin in tablet presentation of 500 mg
Study NCT02778776 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Agave inulin
Description: Oligofructan in powder obtained from agave plant, it was given to each patient a full 10 mg container.
Study NCT02778776 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Agave inulin
Description: Oligofructan in powder obtained from agave plant, it was given to each patient a full 10 mg container.
Study NCT02778776 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo of agave inulin
Description: Calcinated magnesia powder
Study NCT02778776 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of agave inulin
Description: Calcinated magnesia powder
Study NCT02778776 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Metformin placebo
Description: Calcinated magnesia tablet
Study NCT02778776 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Metformin placebo
Description: Calcinated magnesia tablet
Study NCT04578717 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Air-abrasion
Description: A clinical air-abrasion unit was used to pre-condition the NCCLs with bioactive glass 45S5 powder for 10 sec. The operating parameters were; air pressure, 20 psi; powder particles size, 20 µm; nozzle angle, 90◦; nozzle-lesion distance, 5 mm and the internal nozzle diameter, 900 µm
Study NCT04578717 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Adhesive application - Etch&rinse
Description: Enamel and dentine were etched using 37% Phosphoric acid for 30 sec and 15 sec respectively. NCCLs were rinsed thoroughly for 20 sec to remove the acid. Excess water was removed using a cotton pellet to leave a moist dentine surface. One coat of bonding adhesive was gently scrubbed on the entire enamel and dentin surface for 20 sec, air dried for 5 sec and light cured for 10 sec using LED curing light. The light intensity of curing unit was calibrated daily using curing radiometer .
Study NCT04578717 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adhesive application - Self-etch
Description: The bonding adhesive was applied to enamel and dentine for 20 sec with agitation, gently air dried and light cured for 10 sec.
Study NCT01316692 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: biopsy
Description: Correlative studies
Study NCT01316692 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunohistochemistry/tissue microarrays
Description: Correlative studies
Study NCT02645747 — intervention group
Intervention type: DRUG
Intervention: Aflibercept (Eylea, BAY86-5321)
Description: Eylea (intravitreal aflibercept) is an anti-Vascular Endothelial Growth Factor (VEGF) drug indicated for neovascular age-related macular degeneration (AMD), visual impairment due to diabetic macular edema (DME) and visual impairment due to macular edema (ME) secondary to central or branched retinal vein occlusion (RVO).~RVO, both branch and central, is the second most common type of retinal vascular disorders after diabetic retinal disease. Central retinal vein occlusion (CRVO) is characterized by an obstruction of the central retinal vein combined with variable amounts of retinal arterial insufficiency.
Study NCT01800604 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pain Self-Management Intervention #1
Description: Pain Self-Management Intervention #1 will consist of four 60-minute sessions conducted in person over four weeks (1 session/week on average), scheduled at times convenient for participants (including evenings and weekends if necessary). The sessions will cover a variety of topics, including the definition of chronic pain, the physiological processes underlying chronic pain, common pain-related conditions such as sleep disturbance, and the effects of chronic pain. Participants will be encouraged to ask questions about and discuss the information presented during the treatment sessions.
Study NCT01800604 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pain Self-Management Intervention #2
Description: Pain Self-Management Intervention #2 will consist of four 60-minute sessions conducted in person over four weeks (1 session/week on average), scheduled at times convenient for participants (including evenings and weekends if necessary). Pain Self-Management Intervention #2 will emphasize cognitive restructuring skills to replace maladaptive pain-related thoughts with adaptive and reassuring ones. These skills include being able to: (1) develop awareness of one's thoughts; (2) identify and evaluate adaptive/helpful vs. unhelpful/maladaptive thoughts; and (3) develop alternative thoughts to maladaptive thoughts that are (a) realistic, (b) accurate, (c) reassuring, and (d) facilitate positive outcomes.
Study NCT01800604 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pain Self-Management Intervention #3
Description: Pain Self-Management Intervention #3 will consist of four 60-minute sessions conducted in person over four weeks (1 session/week on average), scheduled at times convenient for participants (including evenings and weekends if necessary). In Pain Self-Management Intervention #3, subjects will relax in a comfortable position with their eyes closed and simply listen to the clinician speak. The clinician will begin the session with a hypnotic induction focusing on being aware of sensations of relaxation, followed by suggestions for decreases in pain intensity and alterations in the sensory experience of what are sometimes uncomfortable sensations so that they are more comfortable.
Study NCT01800604 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pain Self-Management Intervention #4
Description: Pain Self-Management Intervention #4 will consist of four 60-minute sessions conducted in person over four weeks (1 session/week on average), scheduled at times convenient for participants (including evenings and weekends if necessary). Pain Self-Management Intervention #4 will use hypnotic strategies and suggestions for identifying adaptive cognitions and for making adaptive changes in cognitions more integrated into a participant's belief system.
Study NCT01680224 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Healthy Weight
Study NCT01680224 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Project Health
Study NCT01680224 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Control
Description: Participants will view a video on overweight and obesity
Study NCT04743037 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: iSMART
Description: This patient-centered and participation-focused self-management intervention will help individuals develop strategies to manage chronic conditions and support their full participation in meaningful life activities.
Study NCT00728507 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifapentine, Moxifloxacin, Pyrazinamide, Isoniazid
Description: Rifapentine:150mg tablets, dose = 300mg for subjects \<= 45kg and 450mg for those >45kg by mouth once a day for 8 weeks; Moxifloxacin 400mg tablet by mouth once a day for 8 weeks, Isoniazid and Pyrazinamide per standard of care for TB treatment.
Study NCT00728507 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isoniazid, Rifampin, Pyrazinamide, Ethambutol
Description: Administered per standard of care for TB treatment
Study NCT02413398 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg
Description: Tablets administered orally once daily for 24 weeks. Randomization will be stratified by pre-enrolment anti-hyperglycemic therapy
Study NCT02413398 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo for Dapagliflozin
Description: Matching Placebo for Dapagliflozin tablets administered orally once daily for 24 weeks
Study NCT04408092 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Granulocyte Macrophage Colony Stimulation Factor
Description: Recombinant Granulocyte Macrophage Colony Stimulation Factor (rGM-CSF) is a hematopoietic growth factor which supports survival, clonal expansion, and differentiation of hematopoietic progenitor cells. rGM-CSF induces partially committed progenitor cells to divide and differentiate in the granulocyte-macrophage pathways. rGM-CSF stimulates the production of monocytes, granulocytes, erythrocytes, and sometimes, megakaryocytes in the bone marrow. It also induces mature macrophages to increase phagocytosis, superoxide generation, Antibody Dependent Cell-mediated Cytotoxicity (ADCC), tumoricidal killing and cytokine production (IL-1 and tumor necrosis factor). GM-CSF was used in the first successful phase III trial of immunotherapy in the pediatric COG protocol, ANBL0931, a national study in high risk neuroblastoma.
Study NCT01893723 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ANI guided remifentanil
Description: remifentanil administration during propofol anesthesia for laparoscopic surgery is ANI guided
Study NCT01893723 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: ANI blind arm
Description: remifentanil administration during propofol anesthesia for laparoscopic surgery is not ANI guided
Study NCT01099410 — intervention group
Intervention type: PROCEDURE
Intervention: Fiberoptic bronchoscopy
Description: which a flexible video instrument is passed via the nose or mouth, through the vocal cords and into the lungs. During the procedure, portions of the lungs will be washed (lavaged) with a salt water solution, to collect the alveolar macrophages. This procedure involves conscious sedation, so that a driver is required on the day of the bronchoscopy. The entire procedure, including placement of an intravenous line to administer medications, local anesthetics, the bronchoscopy itself, and the recovery period, takes about 2.5-3 hours.
Study NCT01099410 — intervention group
Intervention type: PROCEDURE
Intervention: blood draw
Description: Blood will be collected at the enrollment visit to test the subject to exclude disorders that would make it unsafe to perform the bronchoscopy, including severe anemia, infection, or disorders of kidney or liver function.
Study NCT01099410 — intervention group
Intervention type: PROCEDURE
Intervention: intravenous catheter
Description: An intravenous catheter is placed on the day of the bronchoscopy to permit administration of sedative medications.
Study NCT03119376 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: COBPEER
Description: At the end of the online training, they can participate in the study and so peer review 1 manuscript randomly selected from our sample with our tool (COBPeer).
Study NCT04364074 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Goodbelly
Description: Consumption of 1 serving of Goodbelly probiotic daily for 6 weeks. This will be followed by an observation period for 6 weeks during which the subjects will not consume Goodbelly.
Study NCT04364074 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: To prepare the placebo, the dietitian will first heat a water bath to 80 degrees Celsius. This removes the lactobacillus plantarum 299v from the probiotic drink
Study NCT01539525 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interview
Description: Motivational Interview provided by either a Nurse or Computer
Study NCT01539525 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Motivational Interview
Description: Motivational Interview provided by either a Nurse or Computer
Study NCT00168558 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Measles vaccine
Description: The children will be randomised to the following three arms:~Arm 1 - Very early two-dose: V (EZ) 4½ mo of age + V (EZ) 9 mo of age.~Arm 2 - 9 months one- or two-dose: V (SW) 9 mo of age + V (SW)/or nothing 18 mo of age.~Arm 3 - 9 months one- or two-dose: V (EZ) 9 mo of age + V (EZ)/or nothing 18 mo of age.~V = measles vaccination, EZ = standard titre Edmonston-Zagreb measles vaccine, SW = standard titre Schwarz measles vaccine
Study NCT01306058 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRC 105
Description: 15 mg/kg intravenous (IV) every 2 weeks
Study NCT02626260 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: adhesive strip
Description: Adhesive strip with a standard adhesive base
Study NCT01323062 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Bavituximab
Description: Administered 3 mg/kg weekly
Study NCT01539525 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Treatment as Usual
Description: Subjects given a brochure listing relevant recovery resources in the local area.
Study NCT02034266 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega-3 supplementation
Description: 5 mL twice daily, administered under the tongue
Study NCT01603251 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Artemether-lumefantrine combination
Description: Artemether-Lumefantrine (AL)combination; a placebo is given together with the first and fifth dose of AL
Study NCT01306058 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: 400 mg twice a day (bid) continuously in a 28 days cycle
Study NCT02004405 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: strengthening exercise
Description: The experimental group (STRE) will receive strengthening training in Station for lifting weight exercises (Flex Mega 8, Flex Fitness Equipment Brand) using the recommendations of the American College of Sports Medicine (ACMS, 2010), twice a week, during 45 minutes for 16 weeks.
Study NCT02004405 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: flexibility exercise
Description: The control group (FLEX) will receive stretching and flexibility exercise training according to the protocol of prescription and previously tested and described in appendix F (Valim et al., 2003), twice a week, during 45 minutes for 16 weeks.
Study NCT01316692 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: TdT-mediated dUTP nick end labeling assay
Description: Correlative studies
Study NCT01627639 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetazolamide
Description: Acetazolamide (1 g IV per day or 2 g IV per day if coprescription of loop diuretics) or Placebo (saline serum) when pure or mixed metabolic alkalosis being present until planned extubation
Study NCT01627639 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT04013763 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: wheat containing skin care products
Description: stop or continue using wheat containing skin care products
Study NCT01316692 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mass spectrometry
Description: Correlative studies
Study NCT00546858 — intervention group
Intervention type: OTHER
Intervention: Physical Examination
Description: Patients will be invited to be evaluated in the Urology Research office at a future date.
Study NCT04575805 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-delivered Combined Cognitive Bias Modification (iCBM-C)
Description: The iCBM-C is online CBM intervention which is the combination of iCBM-I and iCBM-A interventions for obsessive-compulsive symptoms delivered in eight sessions, twice per week for 4 weeks. The presentation order of the two intervention components will be counterbalanced to allow exploration of any order effects. Thereby, half of the participants in iCBM-C group will complete the iCBM-A task followed by iCBM-I, while the other half will complete the iCBM-I task followed by iCBM-A during each session.
Study NCT04575805 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-delivered Cognitive Bias Modification-Interpretation (iCBM-I)
Description: The iCBM-I is online CBM intervention for obsessive-compulsive symptoms comprised of delivery of OCD related scenarios taking place over eight sessions, twice per week for 4 weeks.
Study NCT01603251 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artemether-lumefantrine combination + single dose Ivermectin
Description: Artemether-lumefantrine (AL) combination + Ivermectin (200ug/kg) given once together with the first dose of AL. A placebo is given together with the fifth dose of AL.
Study NCT01603251 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artemether-lumefantrine combination + repeated dose Ivermectin
Description: Artemether-lumefantrine (AL) combination + Ivermectin (200ug/kg) given together with the first and fifth dose of AL.
Study NCT00920465 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mifegyne and cytotec
Description: One day dosage versus two days dosage
Study NCT00920465 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mifegyne and cytotec
Description: One day dosage versus two days dosage
Study NCT03388983 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 6-week prehabilitation
Description: Participants will be trained at 3 sessions/week for 6 weeks before the surgery to enhance the overall muscle strength, endurance and spinal stability. A physiotherapist/physical trainer in the participating hospital will supervise the preoperative training. The 45-minute exercise regime will include warm-up and cool-down exercises, and a cardiovascular training on a stationary bicycle, stabilization exercises with emphasis on co-contraction of abdominal and back muscles, and hip raise and hip abduction exercises. The number of repetitions and sets of each exercise will be determined based on individual's ability. Each exercise will be slightly modified based on individual progress. The exercise intensity and complexity will be increased over time.
Study NCT00835094 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mometasone furoate
Description: MF-DPI 400 mcg once daily in the morning for 12 weeks
Study NCT00835094 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mometasone furoate
Description: MF-DPI 400 mcg once daily in the evening for 12 weeks